Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PTGFR | P43088 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799224 | 0.93 | PDE10A (0.45) | PDE10ACYP3A4PTGFRPOLBRAB9A | |
| SCHEMBL1801601 | 0.86 | HPGDS (0.58) | PDE10ACHEK2CYP3A4PTGFRHPGDS | |
| SCHEMBL1801599 | 0.81 | HPGDS (0.49) | PDE10ACYP3A4PTGFRHPGDSRAB9A | |
| SCHEMBL1803167 | 0.81 | HPGDS (0.52) | CHEK2HPGDS | |
| SCHEMBL1800512 | 0.80 | CHEK2 (0.56) | CHEK2HPGDSRAB9AALDH1A1 | |
| SCHEMBL1801237 | 0.78 | HPGDS (0.50) | CHEK2HPGDSRAB9AALDH1A1 | |
| SCHEMBL1801109 | 0.77 | HPGDS (0.59) | CHEK2HPGDSPOLBRAB9AALDH1A1 | |
| SCHEMBL1803162 | 0.73 | HPGDS (0.45) | CHEK2HPGDS | |
| SCHEMBL1800509 | 0.72 | CHEK2 (0.47) | CHEK2HPGDS | |
| SCHEMBL1801106 | 0.72 | RAB9A (0.53) | HPGDSPOLBRAB9AMAPK14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1911755-B1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7951956-B2 | Benzoimidazole compound capable of inhibiting prostaglandin D synthetase | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090281098-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1911755-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281098-A1 | BENZOIMIDAZOLE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHETASE | PTGS1, PTGIS, PTGES | PDE10A 1286/4885CHEK2 3558/4885CYP3A4 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.